TCGA-E2-A14O-01A-31R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 45
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- ESTROGEN_RESPONSE_LATE+0.380
- FATTY_ACID_METABOLISM+0.380
- MYC_TARGETS_V2+0.380
- ESTROGEN_RESPONSE_EARLY+0.370
- MTORC1_SIGNALING+0.310
- GLYCOLYSIS+0.290
- ADIPOGENESIS+0.280
- XENOBIOTIC_METABOLISM+0.280
Top 10 suppressed
- MITOTIC_SPINDLE-0.400
- HEDGEHOG_SIGNALING-0.390
- TGF_BETA_SIGNALING-0.390
- KRAS_SIGNALING_UP-0.370
- ALLOGRAFT_REJECTION-0.330
- UV_RESPONSE_DN-0.330
- WNT_BETA_CATENIN_SIGNALING-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- INFLAMMATORY_RESPONSE-0.250
- INTERFERON_ALPHA_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0IA-01A-11R-A034-07 | — | B | 0.853 |
| 2 | AUR-AD9I-TTM3-A-1-1-R-A542-39 | — | C | 0.852 |
| 3 | SRR1313126 | — | C | 0.838 |
| 4 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.835 |
| 5 | TCGA-E9-A1RG-01A-11R-A14D-07 | — | B | 0.831 |
| 6 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.828 |
| 7 | TCGA-66-2766-01A-01R-0851-07 | — | cohortSQ2 | 0.825 |
| 8 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.816 |
| 9 | TCGA-18-3412-01A-01R-0980-07 | — | cohortSQ2 | 0.816 |
| 10 | MBCProject_0040_T2_RNA | — | C | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.380 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |